INTRODUCTION: @entity726 is a common sight-threatening condition that is primarily treated by lowering intraocular pressure (IOP). Today the mainstay of treatment is @entity551 medications; many @entity1 require more than one agent to achieve target IOP. For such @entity1 , fixed combination formulations have several advantages including simplicity of treatment regimen, adherence to the treatment regimen, efficacy, improved ocular surface comfort and reduced cost. All currently available fixed combinations contain a b-blocker, which is contraindicated in some @entity1 . Hence there is a clinical need for fixed-combination preparations without a b-blocker. This paper reviews the current literature on a new fixed-combination drug containing @entity15572 1% and @entity16495 0.2% (BBFC). AREAS COVERED: A PubMed, Embase and ClinicalTrials.gov registry search was performed to identify all relevant studies. Four published clinical papers pertaining to three randomized controlled trials were identified for review. All studies demonstrated a significant reduction (p < 0.01) in mean IOP in @entity1 administered with BBFC compared with its individual components, @entity15572 1% or @entity16495 0.2%. Adverse effects from BBFC were no different from each of the individual components, the most common @entity227 , eye @entity146 and @entity2342 ( @entity1109 ). Although BBFC use was associated with more adverse effects compared with the individual components used as monotherapy (p < 0.001), the cumulative adverse effect profile from BBFC did not appear greater than one would expect from the simultaneous use of the two components. EXPERT OPINION: BBFC is a potential alternative to other fixed-combination medications and is especially useful when topical b-blockers are contraindicated. Longer-term experience will determine if additional adverse effects occur or if efficacy is maintained over longer periods.

@entity15572 plus XXXX for the treatment of @entity726 : an update.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity15572 :: ('MESH:C111827', 'Chemical') :: ['brinzolamide'] @entity227 :: ('MESH:D014786', 'Disease') :: ['being blurred vision'] @entity146 :: ('MESH:D001523', 'Disease') :: ['irritation'] @entity1109 :: ('MESH:D012678', 'Disease') :: ['abnormal taste sensation'] @entity726 :: ('MESH:D005901', 'Disease') :: ['Glaucoma'] @entity16495 :: ('MESH:C015620', 'Chemical') :: ['brimonidine'] @entity551 :: ('MESH:D007022', 'Disease') :: ['topical ocular hypotensive'] @entity2342 :: ('MESH:D004408', 'Disease') :: ['dysgeusia']
@entity16495 :: (MESH:C015620,Chemical) :: ['brimonidine']
